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ABSTRACT
Therapy for polymyalgia rheumatica (PMR) varies widely
in clinical practice as international recommendations for
PMR treatment are not currently available. In this paper,
we report the 2015 European League Against
Rheumatism (EULAR)/American College of Rheumatology
(ACR) recommendations for the management of PMR.
We used the Grading of Recommendations, Assessment,
Development and Evaluation (GRADE) methodology as a
framework for the project. Accordingly, the direction and
strength of the recommendations are based on the
quality of evidence, the balance between desirable and
undesirable effects, patients’ and clinicians’ values and
preferences, and resource use. Eight overarching
principles and nine speciﬁc recommendations were
developed covering several aspects of PMR, including
basic and follow-up investigations of patients under
treatment, risk factor assessment, medical access for
patients and specialist referral, treatment strategies such
as initial glucocorticoid (GC) doses and subsequent
tapering regimens, use of intramuscular GCs and disease
modifying anti-rheumatic drugs (DMARDs), as well as
the roles of non-steroidal anti-rheumatic drugs and non-
pharmacological interventions. These recommendations
will inform primary, secondary and tertiary care
physicians about an international consensus on the
management of PMR. These recommendations should
serve to inform clinicians about best practices in the care
of patients with PMR.
INTRODUCTION
There are wide variations in the treatment of poly-
myalgia rheumatica (PMR) with respect to gluco-
corticoid (GC) dosages, tapering strategies, use of
disease modifying anti-rheumatic drugs (DMARDs)
and duration of treatment. Up to 29–45% of patients
with PMR do not adequately respond to GCs within
3–4 weeks. Relapses and long-term GC dependency
are common.1–4 GC side effects are frequently
observed, occurring in around 50% of patients, and
present a further challenge.5 6 Well considered, inter-
national recommendations can serve to standardise
practice and improve patient care.
Primary objective of the recommendations
These recommendations are intended for the man-
agement of patients with PMR in various settings and
are based on clinical evidence and expert opinion
including informed patient decision-making.
Target population
The target population are patients with PMR based
on clinician diagnosis which may be supported by
Guidelines and recommendations developed and/or
endorsed by the American College of
Rheumatology (ACR) are intended to provide
guidance for particular patterns of practice and not
to dictate the care of a particular patient. The ACR
considers adherence to these guidelines and
recommendations to be voluntary, with the
ultimate determination regarding their application
to be made by the physician in light of each
patient's individual circumstances. Guidelines and
recommendations are intended to promote
beneﬁcial or desirable outcomes but cannot
guarantee any speciﬁc outcome. Guidelines and
recommendations developed or endorsed by the
ACR are subject to periodic revision as warranted
by the evolution of medical knowledge,
technology, and practice.
The American College of Rheumatology is an
independent, professional, medical and scientiﬁc
society which does not guarantee, warrant, or
endorse any commercial product or service.
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currently available diagnostic or classiﬁcation criteria.3 4 7–11
Management of PMR with concomitant giant cell arteritis
(GCA), rheumatoid arthritis (RA) or other conditions that
present with PMR features or mimic PMR is not addressed by
these recommendations.
Target users
The target users of these recommendations are primary, secondary
and tertiary care physicians (that is, general practitioners (GPs),
specialists in general (internal) medicine and rheumatologists).
METHODS
For a detailed description of methods, see online supplementary
ﬁle S1.
In brief, we used the Grading of Recommendations,
Assessment, Development and Evaluation (GRADE) methodology
as a framework.12–15 We formulated 12 PICO (problem/
population, intervention, comparison, and outcome) questions on
interventions and 10 questions on prognostic factors (see online
supplementary box S1A and S1B, or the accompanying paper by
Dejaco et al16). The systematic literature review (SLR) was con-
ducted by two investigators (CDe and YPS) using Ovid
MEDLINE, Embase, PubMed, CINAHL, Web of Science and the
Cochrane Library databases (from January 1970 until April 2014),
and applying the thesauri of PMR, text words, abbreviations and
truncated text words. Outcome parameters used in the SLR may
be found in supplementary box S2. Quality appraisal of
interventional and prognostic studies was performed using
GRADE17 18 and the Quality in Prognostic Studies (QUIPS)
tool,19 respectively. According to GRADE methodology, a guide-
line panel should consider the following aspects when formulating
recommendations: (1) overall quality of evidence; (2) balance
between desirable and undesirable effects; (3) patients’ and clini-
cians’ values and preferences; and (4) resource use. External evi-
dence (from other American College of Rheumatology (ACR)/
European League Against Rheumatism (EULAR) recommenda-
tions; see online supplementary table S1 for details) on safety
aspects related to the use of non-steroidal anti-inﬂammatory drugs
(NSAIDs), GCs and methotrexate (MTX) was taken into account
as indirect evidence, in order to identify the optimal trade-off
between the beneﬁt and harm of interventions. Prognostic factors
were used to build subgroups and to adapt the recommendations
based on the presence or absence of unfavourable prognostic
factors. Final recommendations were either ‘in favour’ or ‘against’
an intervention, and were graded as ‘conditional’ or ‘strong’.
A strong recommendation in favour (against) was considered when
the panel was certain that beneﬁts did (did not) outweigh risks and
burdens, the preferences/values of patients were met (not met) and
resource use was reasonable (unreasonably high). If uncertainty
existed, a conditional recommendation was made.
RESULTS
The results of the SLR are reported in a separate manuscript.16
See online supplementary ﬁle S2 for a summary of the SLR and
external evidence considered by the guideline panel.
General aspects
These recommendations should be understood as clinical advice
and do not dictate the care of a particular patient. The EULAR
and ACR consider adherence to these recommendations to be
voluntary, with the physician making the ultimate decision to
apply them in light of each patient’s individual circumstances.
Overarching principles for the management of PMR
The group agreed upon several principles deemed to be funda-
mental aspects of clinical care in PMR as detailed in box 1.
These principles have not directly resulted from the SLR, but
are consensus based. They are intended as a framework for the
implementation of the speciﬁc treatment recommendations and
are of a general ‘overarching’ nature, a concept adapted from
earlier EULAR recommendations.20–22
Speciﬁc recommendations
See box 1 for a summary of the recommendations. A ﬂow-chart
for the management of PMR patients is depicted in ﬁgure 1.
Recommendation 1: (PICO 1) The panel strongly recom-
mends using GCs instead of NSAIDs in patients with PMR,
with the exception of possible short-term use of NSAIDs and/or
analgesics in PMR patients with pain related to other conditions
(eg, co-existing osteoarthritis). No speciﬁc recommendation can
be made for analgesics.
Explanation: The group recommends strongly against the use
of NSAIDs compared to GCs in the treatment of PMR since the
relative harm of long-term NSAID use (as mainly indicated by
external evidence) outweighs the possible small beneﬁts in
PMR. No speciﬁc recommendation can be made for analgesics.
On a basis of consensus, the panel recognised that the short-
term use of NSAIDs and/or analgesics may be necessary in the
setting of pain related to conditions other than PMR.
Recommendation 2: (PICO 2) The panel strongly recom-
mends using the minimum effective individualised duration of
GC therapy in PMR patients.
A more speciﬁc recommendation is not possible due to the
lack of published evidence on this issue. On a basis of consensus
and in accordance with the overarching principles, the group
unanimously agreed to choose the minimum effective individua-
lised duration and dose of GCs to balance beneﬁt versus harm
after assessing risk factors for GC-related adverse events,
comorbidities, concomitant medications, relapses and prolonged
therapy. Our recommended GC tapering schedule (see
Recommendation 4) assumes a minimum of 12 months of treat-
ment. A more speciﬁc statement is not possible because of the
lack of PMR studies on this particular topic and because of the
multiple subgroups and factors that need to be taken into
account.
Recommendation 3: (PICOs 3–5) The panel conditionally
recommends using the minimum effective GC dose within a
range of 12.5–25 mg prednisone equivalent daily as the initial
treatment of PMR. A higher initial prednisone dose within this
range may be considered in patients with a high risk of relapse
and low risk of adverse events, whereas in patients with relevant
comorbidities (eg, diabetes, osteoporosis, glaucoma, etc) and
other risk factors for GC-related side effects, a lower dose may
be preferred. The panel discourages conditionally the use of
initial doses ≤7.5 mg/day and strongly recommends against the
use of initial doses >30 mg/day.
According to the SLR on prognostic factors and based on clin-
ical experience, the group agreed upon the existence of various
PMR subgroups that are characterised by different risks of
relapse, prolonged GC therapy and/or GC-related adverse
events as well as by various comorbidities and co-medications.
As there are insufﬁcient data to make evidence-based recom-
mendations for all conceivable subgroups, and taking current
clinical practice into account,28–30 the panel agreed upon the
use of the minimum effective GC dose out of a range of 12.5–
25 mg prednisone equivalent daily balancing beneﬁts versus
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Box 1 Summary of the 2015 European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR)
recommendations for the management of polymyalgia rheumatica (PMR)
Target population:
Patients with PMR based on clinician diagnosis which may be supported by currently available diagnostic or classiﬁcation criteria.3 4 7–11
Overarching principles for the management of PMR:
A. Adoption of a safe and speciﬁc approach to ascertain the PMR case deﬁnition. The clinical evaluation should be directed towards
exclusion of relevant mimicking (eg, non-inﬂammatory, inﬂammatory (such as giant cell arteritis or rheumatoid arthritis),
drug-induced, endocrine, infective and neoplastic) conditions.
B. Every case of PMR should have the following assessments prior to the prescription of therapy (primary or secondary care):
▸ Documentation of a basic laboratory dataset. This will help to exclude mimicking conditions and establish a baseline for
monitoring of therapy. This should include rheumatoid factor and/or anti-cyclic citrullinated peptide antibodies (ACPA),
C-reactive protein and/or erythrocyte sedimentation rate (ESR), blood count, glucose, creatinine, liver function tests, bone proﬁle
(including calcium, alkaline phosphatase) and dipstick urinalysis. Additional investigations to consider are protein
electrophoresis, thyroid stimulating hormone (TSH), creatine kinase and vitamin D.
▸ Depending on clinical signs and symptoms and the likelihood of the alternative diagnoses, additional more extensive serological
tests such as anti-nuclear antibodies (ANA), anti-cytoplasmic neutrophil antibodies (ANCA) or tuberculosis tests may be
performed to exclude mimicking conditions. Additional investigations such as chest radiographs may be considered at the
discretion of the physician in order to exclude other diagnoses.
▸ Determination of comorbidities (particularly hypertension, diabetes, glucose intolerance, cardiovascular disease, dyslipidaemia,
peptic ulcer, osteoporosis (and particularly recent fractures), presence of cataract or (risk factors for) glaucoma, presence of
chronic or recurrent infections, and co-medication with non-steroidal anti-inﬂammatory drugs (NSAIDs) as outlined in Smolen
et al21 and Gossec et al,22 other relevant medications and risk factors for steroid-related side effects. Female sex was associated
with a higher risk of glucocorticoid (GC) side effects in low to moderate quality studies.23–25
▸ The role of risk factors for relapse/prolonged therapy is not clear yet. Baseline factors that were associated in low to moderate
quality studies with a higher relapse rate and/or prolonged therapy in PMR studies were: female sex,24 26 high ESR (>40 mm/1st
hour)26–31 and peripheral inﬂammatory arthritis.32 A number of equally low to moderate quality studies, however, failed to
demonstrate an association between these factors and relapse/prolonged therapy.27–30 32–44
C. Consideration of specialist referral, particularly in case of atypical presentation (such as peripheral inﬂammatory arthritis, systemic
symptoms, low inﬂammatory markers, age <60 years), experience of or high risk of therapy-related side effects, PMR refractory to
GC therapy, and/or relapses/prolonged therapy.
D. Treatment of PMR patients should aim at the best care and must be based on a shared decision between the patient and the
treating physician.
E. Patients should have an individualised PMR management plan. Patient perspective and preferences should be considered in the
individualised choice of initial GC dose and subsequent tapering of GCs in PMR.
F. Patients should have access to education focusing on the impact of PMR and treatment (including comorbidities and disease
predictors) and advice on individually tailored exercise programmes.
G. Every patient treated for PMR in primary or secondary care should be monitored with the following assessments: risk factors and
evidence for steroid-related side effects, comorbidities, other relevant medications, evidence and risk factors for relapse/prolonged
therapy. Continuous documentation of a minimal clinical and laboratory dataset should be conducted while prescribing GCs.
Follow-up visits are suggested every 4–8 weeks in the ﬁrst year, every 8–12 weeks in the second year, and as indicated in case of
relapse or as prednisone is tapered and discontinued.
H. It is important for patients to have rapid and direct access to advice from doctors, nurses or trained allied healthcare staff to report
any changes in their condition such as ﬂares and adverse events.
Speciﬁc recommendations for the management of PMR patients:
1. The panel strongly recommends using GC instead of NSAIDs in patients with PMR, with the exception of possible short-term use of
NSAIDs and/or analgesics in PMR patients with pain related to other conditions. No speciﬁc recommendation can be made for
analgesics.
2. The panel strongly recommends using the minimum effective individualised duration of GC therapy in PMR patients.
3. The panel conditionally recommends using the minimum effective GC dose within a range of 12.5–25 mg prednisone equivalent
daily as the initial treatment of PMR. A higher initial prednisone dose within this range may be considered in patients with a high
risk of relapse and low risk of adverse events, whereas in patients with relevant comorbidities (eg, diabetes, osteoporosis,
glaucoma, etc) and other risk factors for GC-related side effects, a lower dose may be preferred. The panel discourages conditionally
the use of initial doses ≤7.5 mg/day and strongly recommends against the use of initial doses >30 mg/day.
4. The panel strongly recommends individualising dose tapering schedules, predicated to regular monitoring of patient disease activity,
laboratory markers and adverse events.The following principles of GC dose tapering are suggested:
A. Initial tapering: Taper dose to an oral dose of 10 mg/day prednisone equivalent within 4–8 weeks.
B. Relapse therapy: Increase oral prednisone to the pre-relapse dose and decrease it gradually (within 4–8 weeks) to the dose at
which the relapse occurred.
C. Tapering once remission is achieved (following initial and relapse therapies): Taper daily oral prednisone by 1 mg every 4 weeks
(or by 1.25 mg decrements using schedules such as 10/7.5 mg alternate days, etc) until discontinuation given that remission is
maintained.
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harms. The panel did not construct case vignettes as a possible
aid for clinical practice; however, it is suggested that a higher
initial prednisone dose (within the given range) may be used in
patients with a high risk of relapse and low risk of adverse
events, whereas in patients with relevant comorbidities (eg, dia-
betes, osteoporosis, glaucoma, etc) and other risk factors for
GC-related side effects, a lower dose may be preferred.
The group conditionally discourages low (≤7.5 mg/day) and
strongly recommends against high (>30 mg/day prednisone
equivalent) initial GC doses. For this statement the group extra-
polated the data from randomised controlled trials,29 31 and took
clinical experience, national PMR guidelines,28–30 as well as
current ACR and/or EULAR recommendations on the use of GCs
in rheumatic diseases into account.32–35 In addition, there is
incontrovertible external evidence of harm from long-term large
doses of GCs32–35 and lack of evidence for any beneﬁt of a high-
dose regimen in PMR. It was unanimously agreed among the
group that patients requiring high doses of GCs should be evalu-
ated for alternate diagnoses and an alternate management plan.
Recommendation 4: (PICO 6) The panel strongly recom-
mends individualising dose-tapering schedules, based on regular
monitoring of patient disease activity, laboratory markers and
adverse events.
The following principles of GC dose tapering are suggested:
A. Initial tapering: Taper dose to an oral dose of 10 mg/day
prednisone equivalent within 4–8 weeks
B. Relapse therapy: Increase oral prednisone to the pre-relapse
dose and decrease it gradually (within 4–8 weeks) to the
dose at which the relapse occurred.
C. Tapering once remission is achieved (following initial and
relapse therapies): Taper daily oral prednisone by 1 mg
every 4 weeks (or by 1.25 mg decrements using schedules
such as 10/7.5 mg on alternate days, etc) until discontinu-
ation as long as remission is maintained.
In accordance with the overarching principles, the panel
agreed upon a strong recommendation to individualise dose
tapering and to regularly monitor PMR patients. Further, the
panel proposed general principles for initial and post-relapse
tapering of GCs (based on consensus and current clinical prac-
tice) but did not ﬁx a schedule as in other guidelines.28–30 The
panel agreed that equivalent objectives may be achieved by alter-
native tapering schedules. For example, a patient with a high
initial prednisone dose (eg, 25 mg/day) may have a fast initial
taper followed by a more gradual decrease in the GC dose,
whereas in a patient starting at a lower initial dose (eg, 12.5 mg/
day), the initial dose may be kept constant for longer and then
eventually reduced.
The group suggested prednisone should be tapered by 1 mg/
4 weeks or similar once remission is achieved. Again, the panel
emphasised the important overall principle of gradual GC reduc-
tion without the need to prescribe a ﬁxed schedule. The group
further recognised that 1 mg prednisone tablets are not available
in all countries (making a reduction of 1 mg/4 weeks unfeasible)
and that other regimens such as alternate day reductions (eg, 10/
7.5 mg on alternate days, etc) are common clinical practice.28
Recommendation 5: (PICO 7) The panel conditionally recom-
mends considering intramuscular (i.m.) methylprednisolone as
an alternative to oral GCs. The choice between oral GCs and
i.m. methylprednisolone remains at the discretion of the treating
physician.
In one clinical trial, i.m. methylprednisolone was applied at a
dose of 120 mg every 3 weeks until week 9. At week 12,
100 mg were used and subsequently, injections were continued
at monthly intervals and the dose was reduced by 20 mg every
12 weeks until week 48. Thereafter, the dose was reduced by
20 mg every 16 weeks until discontinuation.23 36
The panel did not specify a clinical phenotype where i.m.
GCs would be appropriate or adequate therapy; however, the
panel agreed that in clinical practice this preparation may be
considered in cases where a lower cumulative GC dose is desir-
able, for example in female patients with difﬁcult to control
hypertension, diabetes, osteoporosis and/or glaucoma.37–39
Nonetheless, the panel acknowledged that there is a lack of con-
vincing evidence showing signiﬁcantly fewer side effects with i.
m. methylprednisolone than with oral GC therapy.
The reasons why the panel did not endorse a strong recom-
mendation for the use of i.m. methylprednisolone are the fol-
lowing: (1) the efﬁcacy of i.m. methylprednisolone is supported
by a single randomised controlled trial and conﬁrmation of
these data is still necessary;23 36 (2) this trial was neither
designed nor powered as a non-inferiority trial and therefore, a
difference between the efﬁcacy of i.m. and oral GC cannot be
excluded; (3) the trial failed to demonstrate a reduction in
GC-related adverse events except for weight gain; (4) the long-
term beneﬁt of this preparation is unknown (particularly with
respect to a possible reduction in GC side effects); and (5) i.m.
methylprednisolone is not available in all countries.
Recommendation 6: (PICO 8) The panel conditionally recom-
mends using a single rather than divided daily doses of oral GCs
for the treatment of PMR, except for special situations such as
prominent night pain while tapering GCs below the low-dose
range (prednisone or equivalent <5 mg daily).
There are no studies available addressing this issue speciﬁcally
in PMR. Based on clinical experience and because of the
5. The panel conditionally recommends considering intramuscular (i.m.) methylprednisolone as an alternative to oral GCs. The choice
between oral GCs and i.m. methylprednisolone remains at the discretion of the treating physician. In one clinical trial, a starting
dose of 120 mg methylprednisolone i.m. injection every 3 weeks was applied.23
6. The panel conditionally recommends using a single rather than divided daily doses of oral GCs for the treatment of PMR, except for
special situations such as prominent night pain while tapering GCs below the low-dose range (prednisone or equivalent <5 mg
daily).
7. The panel conditionally recommends considering early introduction of methotrexate (MTX) in addition to GCs, particularly in
patients at a high risk for relapse and/or prolonged therapy as well as in cases with risk factors, comorbidities and/or concomitant
medications where GC-related adverse events are more likely to occur. MTX may also be considered during follow-up of patients
with a relapse, without signiﬁcant response to GC or experiencing GC-related adverse events. MTX has been used at oral doses of
7.5–10 mg/week in clinical trials.24–27
8. The panel strongly recommends against the use of TNFα blocking agents for treatment of PMR.
9. The panel conditionally recommends considering an individualised exercise programme for PMR patients aimed at the maintenance
of muscle mass and function, and reducing risk of falls especially in older persons on long-term GCs as well as in frail patients.
10. The panel strongly recommends against the use of the Chinese herbal preparations Yanghe and Biqi capsules in PMR patients.
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concern that adverse events (including disturbance of the
hypothalamic–pituitary–adrenal axis) may be higher with
divided doses, the group agreed against the general use of
divided GC doses in PMR.40–43 The effectiveness and
acceptability of a single daily GC dose has been standard clinical
practice in PMR and other inﬂammatory conditions44 45 and
evening doses can cause circadian rhythm and sleep
disturbances.46
Figure 1 Algorithm based on the 2015 European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR)
recommendations for the management of polymyalgia rheumatica (PMR). The algorithm is applied to patients with PMR based on clinician
diagnosis which may be supported by currently available diagnostic or classiﬁcation criteria.3 4 7–11 The algorithm assumes the consideration of
overarching principles emphasising the importance of assessing comorbidities, other relevant medications and possible risk factors for steroid-related
side effects and relapse/prolonged therapy. In addition, patients diagnosed in primary care should be considered for specialist referral, particularly in
case of atypical presentation (such as peripheral inﬂammatory arthritis, systemic symptoms, low inﬂammatory markers, age <60 years), experience
or high risk of therapy-related side effects and/or relapse/prolonged therapy. A minimal clinical and laboratory dataset should be documented in
each patient before prescribing therapy. 1Examples for comorbidities associated with an increased risk of glucocorticoid (GC)-related side effects are
(according to Duru et al32 and Hoes et al35): hypertension, diabetes, glucose intolerance, cardiovascular disease, dyslipidaemia, peptic ulcer,
osteoporosis (and particularly recent fractures), presence of cataract or (risk factors for) glaucoma, presence of chronic or recurrent infections, and
co-medication with NSAIDs. 2A baseline factor that was associated with a higher risk of GC-related adverse events in PMR studies was: female
sex.37–39 3The role of risk factors for relapse/prolonged therapy is not yet clear. Baseline factors that were associated with a higher relapse rate
and/or prolonged therapy in PMR studies were: female sex,38 47 high erythrocyte sedimentation rate (ESR) (>40 mm/1st hour)47–51 53 and peripheral
inﬂammatory arthritis.54 A number of studies, however, failed to demonstrate an association between these factors and relapse.48–51 54 67–78 4Use
the minimum effective dose out of a range of 12.5–25 mg prednisone equivalent daily: a high risk of relapse/prolonged therapy favours a higher
dose, while a high risk of side effects favours a lower dose. 5In one randomised controlled trial, 120 mg methylprednisolone intramuscular (i.m.)
injection was used every 3 weeks as a starting dose.23 I.m. methylprednisolone may not be available in all countries and the possible long-term
beneﬁt in terms of efﬁcacy and GC-sparing effects of this preparation is unknown. 6Methotrexate (MTX) has been used at oral doses of
7.5–10 mg/week in clinical trials.24–27 7Clinical improvement should be noted after 2 weeks, and almost complete response can be expected after
4 weeks. The deﬁnition of response criteria was beyond the scope of this project; however, a deﬁnition of response was proposed in Dasgupta
et al.3 4 8For initial GC tapering, we recommend reducing the oral dose gradually to a dose of 10 mg/day prednisone equivalent within 4–8 weeks;
after relapse therapy the dose should be decreased gradually (within 4–8 weeks) to the dose at which the relapse occurred. For i.m.
methylprednisolone, a dose of 120 mg every 3 weeks was used for the ﬁrst 9 weeks in Dasgupta et al.23 No recommendation about dose
adjustments of MTX can be made. 9The deﬁnition of criteria for remission and relapse was beyond the scope of this project. Deﬁnitions of remission
and relapse used in clinical studies are summarised in Dejaco et al.65 10Once remission is achieved (following initial and relapse therapies), taper
oral prednisone by 1 mg/4 weeks (or similar, eg, 2.5 mg/10 weeks) until discontinuation given that remission is maintained. In case i.m.
methylprednisolone is used, the following tapering regimen was previously applied:23 100 mg methylprednisolone i.m. at week 12, then
continuation of the injections at monthly intervals with the dose reduced by 20 mg every 12 weeks until week 48. Thereafter, the dose was reduced
by 20 mg every 16 weeks until discontinuation. 11The group suggests that PMR patients be followed up every 4–8 weeks in the ﬁrst year, every
8–12 weeks in the second year and as indicated in case of relapse or as prednisone is tapered off. 12No recommendation can be made for minimal/
optimal duration of therapy. In case patients are treated with a combination of GCs plus MTX and GCs have been withdrawn already,
discontinuation of MTX may be considered. 13Initial lack of response (eg, insufﬁcient improvement of symptoms within 2 weeks): increase oral dose
up to 25 mg prednisone equivalent. In case i.m. methylprednisolone is used, consider switching to oral GCs. Relapse therapy: increase dose to the
previously effective (ie, pre-relapse) dose.
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In special situations such as in case of night pain while taper-
ing below the low-dose range (prednisone or equivalent <5 mg
daily), split doses may be considered. However, persistent break-
through symptoms should prompt re-consideration of the
diagnosis.
Recommendation 7: (PICO 9) The panel conditionally recom-
mends considering early introduction of MTX in addition to
GCs, particularly in patients at high risk of relapse and/or pro-
longed therapy as well as in cases with risk factors, comorbid-
ities and/or concomitant medications where GC-related adverse
events are more likely to occur. MTX may also be considered
during follow-up in patients with a relapse, without a signiﬁcant
response to GC or experiencing GC-related adverse events.
In clinical trials, MTX has been used at oral doses of 7.5–
10 mg/week.24–27
Similar to the explanation of Recommendation 5, the panel
felt that there is no clinical prototype unconditionally warrant-
ing treatment with MTX, rather the use of this drug should be
discussed on an individual basis. In clinical practice, MTX may
be considered for example in female patients36–39 47 with high
initial erythrocyte sedimentation rate (ESR) (>40 mm/1st
hour),48–53 peripheral inﬂammatory arthritis54 and/or comorbid-
ities that may be exacerbated by GC therapy.
The panel also reached a consensus that MTX should be con-
sidered in patients who have relapsed (either on or off GCs),
cases without signiﬁcant response to GC or patients experien-
cing GC-related adverse events. The group further agreed that
MTX may be used with oral or i.m. GC preparations even if the
concomitant use of MTX and i.m. methylprednisolone has not
been tested formally.
The efﬁcacy of MTX was addressed in four randomised
controlled trials and one retrospective study testing the use of
MTX plus oral GCs (initial prednisone doses ranging from 15 to
25 mg/day).24–27 51 There was moderate to high quality of evi-
dence (QoE) from studies indicating a beneﬁt of MTX regarding
remission (1 study),27 relapse rate (1 study),24 discontinuation of
GC (1 study)24 and cumulative GC doses (3 studies).24 26 27
Evidence from one to four studies (1 related to remission, 4 to
relapse, 1 to discontinuation of GC) indicating no beneﬁt regard-
ing these outcomes was of very low quality.25–27 51
The reasons why the panel did not support a stronger recom-
mendation for the use of MTX in PMR are the following: (1) the
total number of patients investigated in randomised trials was
small (n=194),24–27 hence further conﬁrmation of the present
data is necessary; (2) results were contradictory in part, although
trials with a negative result had a very low QoE; (3) a reduction
in GC-related adverse events with the use of MTX has not been
demonstrated. The power of the prospective studies to address
this outcome, however, was insufﬁcient. The panel nevertheless
felt that earlier discontinuation of GC24 and a lower cumulative
GC dose in MTX users26 27 decreases the likelihood of
GC-related side effects; and (4) the cost-effectiveness of MTX
use in PMR is not clear. More frequent prescriptions of MTX
may lead to higher utilisation of healthcare resources in the short
term (eg, because of specialist referral, monitoring visits, blood
tests, etc) but may in the long term save costs by reducing
GC-related side effects. Future studies are necessary to clarify
this issue.
The group recognised that no recommendation can be made
for the use of other non-biologic (ie, conventional synthetic and
conventional targeted) DMARDs in PMR because of the lack of
good evidence from PMR studies. Hydroxychloroquine was
investigated by a single very low QoE retrospective study report-
ing no beneﬁt regarding relapse rate.51
Recommendation 8: (PICOs 10–11) The panel strongly
recommends against the use of TNFα blocking agents for the
treatment of PMR.
The group agreed strongly against the use of TNFα blocking
agents in PMR at this time since there is no evidence for
beneﬁt, but there is a considerable risk of potential harm and
high resource use.55
No recommendation can be made for other biologic agents as
no prospective trials have been published so far. There is one
ongoing randomised study on the use of tocilizumab (clinical-
trials.gov NCT01396317) and another three-arm trial compar-
ing secukinumab, canakinumab and GCs (clinicaltrials.gov
NCT01364389) in PMR. The results of these studies may lead
to a modiﬁcation of this recommendation.
Recommendation 9: (PICO 12) The panel conditionally
recommends considering an individualised exercise programme
for PMR patients aimed at the maintenance of muscle mass and
function, and reducing risk of falls.
There are no studies investigating the value of non-
pharmacological therapies (eg, physiotherapy, relaxation techniques,
diets, etc) in PMR and there is insufﬁcient clinical experience on this
issue to agree on a speciﬁc recommendation. Nevertheless, the panel
agreed on recommending an individualised exercise programme
(see overarching principles) in view of its beneﬁt for maintaining
muscle mass and function and reducing risk of falls, especially in
older persons on long-term GCs as well as in frail patients.
Use of herbal preparations in PMR
The panel strongly recommends against the use of the Chinese
herbal preparations Yanghe and Biqi capsules in PMR patients.
There were some discussions about whether herbal prepara-
tions could be considered non-pharmacological interventions
(and were therefore within the scope of PICO 12); however, the
panel felt the need for comment on this issue because several pre-
parations are available which may be popular with PMR patients.
The SLR identiﬁed two studies testing Chinese Yanghe herb
decoction and Chinese Biqi capsules in PMR patients.56 57 For
Chinese Yanghe there is moderate QoE for a lower ESR at week
8 (mean difference 6.0 mm/h) and 12 (6.4 mm/h) and very low
QoE indicating a lower rate of GC-related adverse events (with
borderline signiﬁcance of the effect estimate) as well as reduced
morning stiffness at week 12.56 For Biqi capsules there is low
QoE indicating a higher response rate at week 12.57
The group nevertheless agreed (after balancing evidence,
beneﬁt/harm, availability and resource use) to recommend
strongly against the regular use of these preparations at this time
for the following reasons: (1) the relevance of the small effect of
Chinese Yanghe herb decoction on ESR is minimal for patients
and good evidence for a clinical beneﬁt of the substance is not
available; (2) neither of the two substances is approved by the US
Food and Drug Administration (FDA) or the European
Medicines Agency (EMA); (3) the generalisability of the evidence
for beneﬁt is unclear; (4) these preparations may have unforesee-
able adverse effects; (5) the availability of high quality prepara-
tions is unclear; and (6) resource impact (ie, costs) is unknown.
Release and implementation of the recommendations
See online supplementary ﬁle S2.
Cost implications and conﬂicts of interest
Cost implications are outside the scope of these
recommendations.
None of the panel members disclosed any conﬂict of interest
associated with the development of these recommendations.
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DISCUSSION
See online supplementary ﬁle S3 for a full-length discussion.
The 2015 EULAR/ACR recommendations for the management
of PMR is the ﬁrst collaborative project between EULAR and
ACR to endorse treatment recommendations in rheumatology.
We recognise that our recommendations are only partially
supported by evidence, and that they do not cover all aspects
important for the management of PMR. The group therefore
unanimously agreed that the research agenda (covering the
evidence gaps related to PMR management) is an important
result of this project (box 2).
Due to our rigorous SLR approach to select high quality
papers, we did not include other reviews, case reports or case
series indicating possible treatment options in
treatment-resistant PMR patients. For example, we found one
earlier SLR reporting similar conclusions regarding the value of
MTX in PMR.58 In addition, two case series were recently pub-
lished on the use of leﬂunomide59 60 and a few case reports are
available on tocilizumab.61–63 Azathioprine has been tested in a
double-blind randomised controlled trial in patients with PMR
and GCA; however, as PMR patients were not analysed separ-
ately, we did not include this study in the SLR.64
It was beyond the scope of this recommendation project to
deﬁne treatment targets in PMR. ‘Clinical improvement’ was
considered as the ﬁrst treatment goal after the initiation of GCs,
and the response criteria used in the 2012 classiﬁcation criteria
study may be considered.3 4 Remission and relapse have been het-
erogeneously deﬁned in the literature, as we pointed out previ-
ously.65 Future prospective studies aimed at the validation of new
deﬁnitions of response, remission and relapse are, therefore,
required to enable a targeted treatment approach in PMR.66
The most important limitations of this project are the paucity
of high quality trials (as mentioned above) and the fact that
GRADE is less well developed for the assessment of rare out-
comes. Consequently, the QoE for adverse events is usually
lower than for efﬁcacy data. This necessitated the use of relevant
external evidence to strengthen this aspect of our
recommendations.
These recommendations should support clinicians to achieve
the best patient outcomes. Further research on existing drugs is
necessary to offer additional, evidence-based treatment options
to our patients. We anticipate an update of these recommenda-
tions 3 years after their publication; however, an earlier revision
may be necessary if new data emerge that would modify the
current recommendations.
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Box 2 Research agenda
The group agreed that future studies in polymyalgia rheumatica (PMR) should be multicentre and properly powered using an agreed,
validated core outcome set and a robust trial design that would maximise the power of studies, facilitate regulatory approvals and allow
future meta-analysis.
Speciﬁc research questions:
1. Which outcome measures including patient-related outcomes, and response, remission and relapse criteria should be used in PMR?
What is the value of a composite score? What are the most relevant treatment targets in PMR?
2. What is the efﬁcacy and safety of different routes of glucocorticoid (GC) administration (oral, intramuscular,
intra-articular), different initial GC doses, various GC tapering regimens, and different GC ﬂare doses?
3. What is the efﬁcacy and safety of DMARDs (non-TNFα biologic, conventional synthetic and conventional targeted) in
PMR? What is the optimal strategy for using DMARDs in PMR: monotherapy versus combination therapy, early versus
late introduction, and (particularly for biologics) use with or without GCs?
4. What is the minimal/optimal duration of therapy and which strategies for withdrawing GCs and/or DMARDs yield the best efﬁcacy/
safety proﬁle?
5. What is the optimal strategy for shared primary and specialty care including recommendations for specialist referral?
How can patients be better involved in treatment decisions, and are there any decision aids? What is the role of
self-management?
6. What is the value of tight control (ie, treat to target) versus conventional management strategies in PMR?
7. How should patients with long-standing disease and long-term low-dose GC therapy be managed?
8. What is the cost utility and effectiveness of DMARD use in PMR (versus GC use alone)?
9. What is the value of non-pharmacological therapies in PMR? Particularly, it is assumed but not yet demonstrated that physiotherapy
may support preservation of function and reduce the risk of adverse events related to GC use. Patients may beneﬁt from exercise by
maintaining muscle mass and function as well as by fall prevention especially in the frail. What is the role of diet in PMR and
nutrition supplements (eg, ﬁsh oil) related to outcomes?
10. What is the efﬁcacy and safety of herbal preparations in PMR?
11. What is the role of imaging (particularly ultrasound) for the assessment and monitoring of PMR, identiﬁcation of overlap with other
diseases (eg, large vessel vasculitis or inﬂammatory arthritis) alongside clinical and patient reported outcomes?
12. Which biomarkers may be useful in PMR? Why do some patients do better than others? How can we identify these
groups and what is the biological mechanism behind it? Should different drugs be applied to different PMR subgroups?
13. What is the morbidity and mortality of PMR patients (with a particular focus on cardiovascular risk) in long-term observational
studies?
14. What is the aetiopathogenesis of PMR? Which targeted therapies could be developed based on new knowledge of disease
mechanisms?
Bolded points indicate the top 5 items of the research agenda according to the opinion of the guideline panel.
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